Recent investigations have centered on the convergence of GLP-1|GIP|glucagon receptor stimulant therapies and DA communication. While GIP stimulators are commonly employed for managing type 2 T2DM, their emerging https://aadamrbqy126944.diowebhost.com/96310427/new-gip-agonists-and-dopaminergic-modulation-a-contextual-overview